[Form 4] Mesa Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Jennifer Sadie Alltoft, a director of Mesa Laboratories, reported changes in her beneficial ownership on Form 4. On 08/15/2025 she had 1,404 restricted stock units (RSUs) vest and be converted into 1,404 shares of common stock at a $0 price, and she acquired an additional 2,784 RSUs that vest on 08/15/2026. After the transactions, she beneficially owned 4,878 shares directly.

The filing was signed under power of attorney by John Sakys on 08/18/2025. The transactions are compensation-related equity awards (vesting and new RSU grant) and reflect routine director equity compensation rather than open-market purchases or sales.

Insights

Financial Analyst

TL;DR: Routine director equity vesting and a forward-dated RSU grant increased direct holdings to 4,878 shares; no cash consideration reported.

This Form 4 shows compensation-driven changes: 1,404 RSUs vested into common shares with a $0 price (typical for vesting) and 2,784 RSUs granted that vest in one year. The net effect is an increase in the director's direct stake to 4,878 shares. Because these transactions are award/vesting-related and not market trades, they are unlikely to signal a change in market sentiment or immediate liquidity events for the issuer.

Corporate Governance Expert

TL;DR: The filing documents standard director compensation mechanics and timely disclosure under Section 16 requirements.

The report indicates compliance with reporting rules: a director received vested RSUs and a future-vesting RSU grant, both disclosed on Form 4 and signed via power of attorney. This is consistent with common board compensation practices and provides transparency on insider holdings; there are no governance red flags, such as undisclosed related-party transfers or open-market sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alltoft Jennifer Sadie

(Last) (First) (Middle)

12100 W. 6TH AVENUE

(Street)

LAKEWOOD CO 80228

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		1,404	A	$0	4,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units - 8	(1)	08/15/2025		M			1,404	(2)	(3)	Common Stock	1,404	$0	0	D
Restricted Stock Units - 9	(1)	08/15/2025		A		2,784		(4)	(3)	Common Stock	2,784	$0	2,784	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested on August 15, 2025

3. Not Applicable

4. RSUs that vest on August 15, 2026

	John Sakys under Power of Attorney by Jennifer Alltoft	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.